Generic placeholder image

Current Respiratory Medicine Reviews


ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Current Approaches for New TB Drugs

Author(s): Shilpika Pandey, Isha Soni, Neha Topno, Arunava Dasgupta and Sidharth Chopra

Volume 10, Issue 2, 2014

Page: [88 - 96] Pages: 9

DOI: 10.2174/1573398X10666140813201210

Price: $65


Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.

Keywords: Clinical strains, drugs, MIC, Mycobacterium, pre-clinical development, tuberculosis.

« Previous
Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy